Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...

Charles Schwab Investment Management Inc. lifted its holdings in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 6.4% in ...

Equities research analysts at Wedbush cut their Q1 2025 EPS estimates for Bicara Therapeutics in a note issued to investors ...

Using nasal swabs to identify a child’s asthma subtype may lead to more precise medication prescribing and development of ...

Two of four puppies found dumped in the woods in Connellsville on March 26 have died, according to a nearby shelter that is ...

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...

A new study out of Spain has ignited discussions around the long-term effects of repeated COVID-19 vaccinations, raising questions about vaccine efficacy and safety that many in the healthcare ...